Patent Application
20240000740
The present invention relates to ω-3 polyunsaturated fatty acids for use in the prevention and treatment of male infertility in prepubertal subjects who are candidates for gonadotoxic therapies. In particular, the invention relates to ω-3 polyunsaturated fatty acids for use in the prevention and treatment of male infertility in prepubertal subjects undergoing chemotherapeutic and/or radiotherapeutic treatments for the treatment of neoplasms.
It is well-known that the recent progress achieved in the field of chemo- and radiotherapy has considerably increased the survival rate of children, adolescents and young men affected by neoplastic pathologies and severe inflammatory diseases having an autoimmune etiology, with a rate of mortality that has fallen constantly by 2.1% a year since 1975 (Siesling S et al., 2014).
However, along with the increase in the survival of patients (at least 3 out of 4) treated with the new chemotherapeutic therapies, a significant increase has been observed in sub-fertile or infertile subjects in adulthood (Siesling S et al., 2014). In fact, the chemo- and radiotherapeutic treatments used exhibit a high cytotoxicity capable of altering or completely compromising the male gonad, with a consequent reduction or loss of endocrine function and fertility (Romerius et al., 2009; Schertl 2007; Williams 2008).
In particular, the chemotherapeutics used in the treatment of malignant and non-malignant pathologies bring about an alteration of spermatogenesis and of the endocrine function of testicles (Nurmio M et al., 2009).
In Italy, on average, over 14 boys aged younger than 15 years receive a tumour diagnosis every day and more than 80% of them are successfully cured (Siesling S et al., 2014). Therefore, the infertility resulting from the therapies carried out to treat neoplasms in the prepubertal period represents a frequent consequence that occurs in adulthood as a result of the treatments carried out (Garolla A et al., 2006).
It is estimated, in fact, that about one third of patients who survive neoplasms treated in the prepubertal period will be azoospermic in adulthood and about one fifth of these subjects will be oligozoospermic (Ntemou and et al., 2019).
The data in the literature suggest that young male patients undergoing chemo- and/or radiotherapy for oncological pathologies appear to be at greater risk of infertility than women of the same age (Hamre 2012).
Whereas in adult males who undergo chemo- and/or radiotherapeutic treatments and/or are candidates for surgical interventions that potentially impair the ejaculatory function, cryopreservation of sperm from seminal fluid by now represents a reliable, well-established method that is increasingly implemented in clinical practice, this method cannot be carried out in prepubertal patients (Tournaye H et al., 2014).
In greater detail, the data in the literature show that treatment with chemotherapeutic drugs in prepubertal subjects induces a reduction in the size of the testicles, a loss of the population of germ cells, the presence of seminiferous tubules consisting solely of Sertoli cells (SCs) due to the loss of germ cells, interstitial fibrosis and thickening of the basal membrane (Hensle T W et al., 1984; Uderzo C et al., 1984).
In particular, it is known that oncological therapies in prepubertal subjects are capable of suppressing the population of testicular germline stem cells (Ad and Ap spermatogonia), which represent the cells from which spermatogenesis originates (Hussein A A et al., 2014). Chemo- and/or radiotherapeutic treatments can in fact result in a complete inhibition of spermatogenesis and ultimately in sterility due to azoospermia (Ntemou and et al., 2019; Stukenborg J B et al., 2018).
It is further known that treatment with chemotherapeutic drugs induces apoptosis of germ cells, as well as a reduction in viability (Aslani et al., 2017) and an alteration of the functionality of SCs (reduction in androgen-binding protein and transferrin) (Favareto et al., 2011). However, information about the modulation of two typical Sertolian markers, namely, the anti-Müllerian hormone (AMH) and inhibin B (Allen C M et al., 2020) is completely lacking.
The number of human spermatogonial stem cells (hSSCs), consisting of spermatogonia A (Ad and Ap), after a gradual reduction from birth to 3 years, subsequently increases until 8 years of age and, finally, after a brief decrease between 8 and 9 years, it increases considerably until 12-13 years of age. In particular, the number of SSCs appears to be unchanged from birth to 12-13 years of age, except during the period between 4 and 10 years, when the number of type Ad spermatogonia decreases slightly compared to type Ap. This period coincides with the appearance of type B spermatogonia, whose number increases progressively from 4 to 12-13 years of age.
Spermarche, that is, the period in which spermatozoa are observable in seminal fluid, occurs at 11 years of age in 1-2% of boys, at 12-13 years of age in 15-37% and at 14 years of age in 24%-69%.
SCs, which represent the only somatic cells within the seminiferous tubules, can be considered the orchestra director of spermatogenesis (Dimitriadis F et al., 2015). The contribution of SCs to spermatogenesis is based on the production of critical factors (components of the extracellular matrix, growth factors and many proteins like transferrin, clusterin and stem cell factor), necessary for the successful development of spermatogonia up to the stage of spermatozoa (Gnessi L et al., 1997; Rossi P et al., 2000).
In particular, SCs produce glial cell-derived neurotrophic factor (GDNF), which, on interacting with the RET/GFRA1 receptor complex located on the surface of undifferentiated spermatogonia, acts like a mitogenic agent, finely regulating the renewal of the residual pool of spermatogonial stem cells, the target of gonadotoxic therapies (Parekh P A et al., 2019).
In recent years a variety of evidence has been gathered regarding the possible correlation existing between the toxicity mediated by chemotherapeutic drugs and the appearance of epigenetic modifications in treated subjects (Quintanilha J C F et al., 2019; Hanf A et al., 2019).
It has already been known for some time, in fact, that DNA methylation, considered as one of the main epigenetic mechanisms, is capable of influencing male fertility (Carrell D T 2012). In particular, “DNA methylation” refers to the conversion of cytosine into 5-methylcytosine by at least 5 types of DNA methyl-transferases (DNMTs). This methylation occurs in so-called “CpG” (cytosine-phosphate-guanine) islands, i.e. in those areas of DNA in which cytosine is directly followed by a guanine in the DNA sequence. This phenomenon triggers a process (enhanced by histone lysine deacetylation) that concludes with a thickening of chromatin, which inactivates the genes involved, preventing the access of transcription factors to promotors. The final result of all this consists in a reduced gene transcription and, de facto, in a gene silencing (Kläver R et al., 2013). The reason for this intense DNA methylation during spermatogenesis, besides that of regulating gene expression, seems tied to the necessity of adequately organising the chromatinic structure for the growing and new needs of meiotic and spermatogenic processes. An anomalous methylation of genomic DNA, equal to about 14.4% of paternal genes, is associated with the presence of oligospermia or oligoasthenoteratozoospermia (Oakes C C et al., 2007). Furthermore, data in the literature demonstrate that the expression of GDNF is subject to mechanisms of epigenetic modification (Saracino R et al., 2020; Zhang L et al., 2019).
It is known that eicosapentaenoic acid (EPA), a fatty acid with known anti-tumour properties, is capable of decreasing the levels of DNA methylation by activating TET proteins and thereby transforming 5-methyl cytosine into 5-hydroxymethylcytosine, with a consequent re-expression of genes silenced in the methylation process (Ceccarelli et al., 2018). Furthermore, EPA is capable of inhibiting the expression and activity of the enzyme histone deacetylase and of DNA methyltransferases (HDAC1 and DNMT), responsible, respectively for deacetylation of the lysine residues of histones and for the addition of methyl groups on the CpG islands of DNA, which represent two of the most studied mechanisms in epigenetic regulation (Ceccarelli V et al., 2020).
Previous studies have demonstrated the protective effect of EPA through the inhibition of apoptosis, lipoperoxidation and the production of active radical oxygen species on cultures of mouse Sertoli cells (Hu X et al., 2018).
Furthermore, patent application WO/2004/056370 describes a fatty acid composition composed of (all the omega-3)-5,8,11,14,17-eicosapentaenoic acid (EPA) and (all the omega-3)-4,7,10,13,16,19 docosahexaenoic acid (DHA), for the production of a pharmaceutical composition or a dietary foodstuff for the prevention or treatment of male infertility. In particular, the fatty acids compositions according to the aforesaid patent application are potentially useful for the treatment and prevention of male infertility in asthenozoospermia and teratozoospermia, in the condition due to low concentrations of DHA in seminal fluid.
However, patent application WO/2004/056370 describes the aforesaid composition of EPA and DHA in the treatment and prevention of male infertility in patients affected by alterations in sperm motility (asthenozoospermia) and morphology (teratozoospermia). Therefore, the composition described in WO/2004/056370 is aimed at the treatment of subjects who have already developed spermatozoa and does not resolve the problem of infertility induced by chemotherapeutics in prepubertal individuals in whom the production of spermatozoa has not yet occurred (and who can thus not cryopreserve semen).
In the light of the foregoing, it appears evident that there is a need to provide new therapies capable of preventing and/or treating male infertility in prepubertal subjects undergoing chemo- and/or radiotherapies.
The solution according to the present invention fits into this context; it aims to provide compounds, in particular polyunsaturated fatty acids of the ω-3 series, for the prevention and treatment of male infertility, in particular azoospermia-induced infertility, due to chemo/radiotherapeutic treatments in prepubertal subjects, wherein cryopreservation cannot take place.
According to the present invention, it has now been found that in SCs of prepubertal pigs treated with cisplatin in the presence of eicosapentaenoic acid (EPA), the gene expression and protein expression of Sertolian GDNF, together with the gene expression and secretion of AMH and inhibin B, are surprisingly recovered. Therefore, according to the present invention, EPA, by acting in the recovery of GDNF and the restoration of Sertolian functionality, in an in “vitro” model of SCs, can be proposed as a therapeutic strategy in the treatment of male infertility due to chemo/radiotherapeutic treatments in prepubertal subjects, wherein cryopreservation cannot take place.
The present invention concerns polyunsaturated fatty acids of the ω-3 series for use in the treatment and prevention of male infertility in subjects undergoing chemo/radiotherapeutic treatments carried out to treat neoplasms in the prepubertal period.
The use of the ω-3 polyunsaturated fatty acids according to the present invention, in particular the use of EPA, advantageously makes it possible to induce the production of new germ cells, avoid a reduction in the number thereof or increase the number thereof in patients undergoing chemo- and/or radiotherapeutic treatments in the prepubertal period, wherein the production of spermatozoa has not yet occurred (and wherein, therefore, semen cannot be cryopreserved).
In particular, the experimental data described below show that, following treatment of SCs with chemotherapeutic drugs, it was possible to observe a significant reduction in hydroxymethylcytosine and a significant reduction in the gene expression of GDNF and of the GDNF protein compared to untreated SCs. Furthermore, a protective effect of EPA was demonstrated at a concentration of 100 μM on SCs treated at the highest dose of cisplatin (3.33 μM). This effect was demonstrated both in terms of gene and protein expression of Sertolian GDNF, and in terms of gene expression and secretion of AMH and inhibin B as specific markers of Sertolian functionality. In particular, Sertolian GDNF was surprisingly recovered compared to the control group and AMH and inhibin B reached values comparable to those of the control group.
This effect is likely to be correlated to the epigenetic action of EPA. In fact, as shown in the experimental data, the demethylating action of EPA was demonstrated when cells were treated with AZA (5-aza-2′-deoxycytidine), a known demethylating agent used in the chemotherapeutic treatment of tumour pathologies. By treating cells with the demethylating agent AZA a recovery in the expression of GDNF was obtained which was comparable to the one induced by treatment with the fatty acid EPA, although the treatment with EPA showed a greater effectiveness. Furthermore, the use of EPA as a demethylating agent advantageously makes it possible to avoid the occurrence of toxic side effects that normally accompany treatments with demethylating agents with a generalised action such as 5-AZA. In fact, EPA, only acts where it is necessary to restore a correct gene expression when the latter is modified.
It is therefore specific object of the present invention one or more ω-3 polyunsaturated fatty acids for use in the prevention and treatment of male infertility, in particular azoospermia-induced infertility, of prepubertal subjects undergoing chemotherapeutic and/or radiotherapeutic treatments, wherein said infertility is caused by said chemotherapeutic and/or radiotherapeutic treatments. Such subjects, not being able to collect semen beforehand for cryopreservation, since physiologically the production of spermatozoa has not yet begun, are in fact at high risk of infertility because of the high gonadotoxicity of such treatments.
According to the present invention, “prepubertal subjects undergoing chemotherapeutic and/or radiotherapeutic treatments” means subjects who have yet to receive the treatment, subjects who are receiving the treatment or subjects who have already received it. Therefore, said one or more ω-3 polyunsaturated fatty acids can be administered before, after or during the chemotherapeutic and/or radiotherapeutic treatment. Preferably, said one or more ω-3 polyunsaturated fatty acids are administered during or after the chemotherapeutic and/or radiotherapeutic treatment, even more preferably said one or more ω-3 polyunsaturated fatty acids are administered during the chemotherapeutic and/or radiotherapeutic treatment.
According to the present invention, said one or more polyunsaturated fatty acids can be selected from the group consisting of 20:5 ω-3 eicosapentaenoic acid, 18:3 ω-3 α-linolenic acid, 22:6 ω-3 docosahexaenoic acid and 22:5 ω-3 docosapentaenoic acid (DPA), preferably 20:5 ω-3 eicosapentaenoic acid.
Therefore, according to the present invention, mixtures of several ω-3 polyunsaturated fatty acids can be administered, for example a mixture of 20:5 ω-3 eicosapentaenoic acid and 22:6 ω-3 docosahexaenoic acid, a mixture of 20:5 ω-3 eicosapentaenoic acid and 18:3 ω-3 α-linolenic acid, a mixture of 20:5 ω-3 eicosapentaenoic acid and 22:5 ω-3 docosapentaenoic acid, a mixture of 22:6 ω-3 docosahexaenoic acid and 18:3 ω-3 α-linolenic acid, a mixture of 18:3 ω-3 α-linolenic acid and 22:5 ω-3 docosapentaenoic acid, a mixture of 22:6 ω-3 docosahexaenoic acid and 22:5 ω-3 docosapentaenoic acid, a mixture of 20:5 ω-3 eicosapentaenoic acid, 18:3 ω-3 α-linolenic acid and 22:6 ω-3 docosahexaenoic acid, a mixture of 20:5 ω-3 eicosapentaenoic acid, 18:3 ω-3 α-linolenic acid and 22:5 ω-3 docosapentaenoic acid, a mixture of 20:5 ω-3 eicosapentaenoic acid, 22:6 ω-3 docosahexaenoic acid and 22:5 ω-3 docosapentaenoic acid, a mixture of 18:3 ω-3 α-linolenic acid, 22:6 ω-3 docosahexaenoic acid and 22:5 ω-3 docosapentaenoic acid or a mixture of 20:5 ω-3 eicosapentaenoic acid, 18:3 ω-3 α-linolenic acid, 22:6 ω-3 docosahexaenoic acid and 22:5 ω-3 docosapentaenoic acid.
It is a further object of the present invention a pharmaceutical composition comprising one or more ω-3 polyunsaturated fatty acids together with one or more pharmaceutically acceptable excipients and/or adjuvants, for use in the prevention and treatment of male infertility, in particular azoospermia-induced infertility, in prepubertal subjects undergoing chemotherapeutic and/or radiotherapeutic treatments, wherein said infertility is caused by said chemotherapeutic and/or radiotherapeutic treatments.
According to the present invention, said one or more ω-3 polyunsaturated fatty acids can be selected from the group consisting of 20:5 ω-3 eicosapentaenoic acid, 18:3 ω-3 α-linolenic acid, 22:6 ω-3 docosahexaenoic acid and 22:5 ω-3 docosapentaenoic acid, preferably 20:5 ω-3 eicosapentaenoic acid.
In particular, according to the present invention, said pharmaceutical composition can comprise mixtures of several ω-3 polyunsaturated fatty acids, for example a mixture of 20:5 ω-3 eicosapentaenoic acid and 22:6 ω-3 docosahexaenoic acid, a mixture of 20:5 ω-3 eicosapentaenoic acid and 18:3 ω-3 α-linolenic acid, a mixture of 20:5 ω-3 eicosapentaenoic acid and 22:5 ω-3 docosapentaenoic acid, a mixture of 22:6 ω-3 docosahexaenoic acid and 18:3 ω-3 α-linolenic acid, a mixture of 18:3 ω-3 α-linolenic acid and 22:5 ω-3 docosapentaenoic acid, a mixture of 22:6 ω-3 docosahexaenoic acid and 22:5 ω-3 docosapentaenoic acid, a mixture of 20:5 ω-3 eicosapentaenoic acid, 18:3 ω-3 α-linolenic acid and 22:6 ω-3 docosahexaenoic acid, a mixture of 20:5 ω-3 eicosapentaenoic acid, 18:3 ω-3 α-linolenic acid and 22:5 ω-3 docosapentaenoic acid, a mixture of 20:5 ω-3 eicosapentaenoic acid, 22:6 ω-3 docosahexaenoic acid and 22:5 ω-3 docosapentaenoic acid, a mixture of 18:3 ω-3 α-linolenic acid, 22:6 ω-3 docosahexaenoic acid and 22:5 ω-3 docosapentaenoic acid or a mixture of 20:5 ω-3 eicosapentaenoic acid, 18:3 ω-3 α-linolenic acid, 22:6 ω-3 docosahexaenoic acid and 22:5 ω-3 docosapentaenoic acid.
According to the present invention, said pharmaceutical composition can further comprise one or more chemotherapeutic agents, preferably chemotherapeutic agents used in paediatric haematology-oncology. In particular, said one or more chemotherapeutic agents can be selected from the group consisting of cisplatin, 4-hydroperoxycyclophosphamide, doxorubicin, gemcitabine, methotrexate, cytosine arabinoside (ARA-C), irinotecan, vincristine, etoposide, dacarbazine, vindesine, vinblastine, vinorelbine, asparaginase, mitoxantrone and docetaxel.
Furthermore, according to the present invention, said pharmaceutical composition can further comprise one or more antioxidant agents. In particular, said one or more antioxidant agents can be selected from the group consisting of vitamin E, vitamin C, beta-carotene, N-acetylcysteine, alpha-lipoic acid, carnitine, folic acid, lycopene, selenium, coenzyme Q-10 and zinc.
The present invention further relates to a combination of one or more ω-3 polyunsaturated fatty acids with one or more agents selected from the group consisting of chemotherapeutic agents and antioxidant agents, for separate or sequential use in the prevention and treatment of male infertility, in particular azoospermia-induced infertility, in prepubertal subjects undergoing chemotherapeutic and/or radiotherapeutic treatments, wherein said infertility is caused by said chemotherapeutic and/or radiotherapeutic treatments.
According to the present invention, said one or more chemotherapeutic agents can be selected from the group consisting of cisplatin, 4-hydroperoxycyclophosphamide, doxorubicin, gemcitabine, methotrexate, cytosine arabinoside (ARA-C), irinotecan, vincristine, etoposide, dacarbazine, vindesine, vinblastine, vinorelbine, asparaginase, mitoxantrone and docetaxel.
Furthermore, according to the present invention, said one or more antioxidant agents can be selected from the group consisting of vitamin E, vitamin C, beta-carotene, N-acetylcysteine, alpha-lipoic acid, carnitine, folic acid, lycopene, selenium, coenzyme Q-10 and zinc.
According to the present invention, “separate use” means the administration, at the same time, of the compounds of the combination according to the invention in distinct pharmaceutical forms. “Sequential use” means the sequential administration of the compounds of the combination according to the invention, each in a distinct pharmaceutical form.
The present invention will now be described by an illustrative, but not limitative, way, according to a preferred embodiment thereof, with particular reference to the examples and figures of the appended drawings, wherein:
Materials and Methods
Isolation and Purity of the SCs
The animal studies were conducted in accordance with national guidelines (approved Italian animal protection certification A-3143-01) and guidelines of the Committee for the Care and Use of Animals of the University of Perugia. The experimental protocols were approved by the University of Perugia. The newborn prepubertal “Large White” pigs (Farm “Trequattrini”, S. Elena di Marsciano, PG), aged 7-15 days, were used as SC donors. The SCs were isolated in accordance with previously established methods, modified in our laboratory (Luca et al., 2015).
Immunostaining for AMH, a specific and unique marker of prepubertal SCs, 3-βHSD, specific for Leydig cells and ASMA, specific for peritubular cells was performed in accordance with previously established methods, with slight modifications (Luca et al., 2015). After the isolation/purification procedure had been completed, the cultures were composed of highly purified SCs (95%), as indicated by the immunostaining for AMH, with an extremely low percentage of “contaminating cells” (5%), (Luca et al., 2015).
Culture of SCs and Treatment with Chemotherapeutic Drugs
The SCs were maintained at 37° C. and 5% CO2 in HAMF-12 (Euroclone, MI, Italy) supplemented with 0.166 nM of retinoic acid (Sigma-Aldrich, St. Louis, MO, USA) and 5 mL/500 ml of ITS (Becton Dickinson cat. no. 354352, NJ, USA) in the absence (untreated) or presence of chemotherapeutic drugs for 48 hours plus 24 of recovery at the following concentrations:
The SCs were maintained at 37° C. and 5% CO2 in HAMF-12 (Euroclone, MI, Italia) supplemented with 0.166 nM of retinoic acid (Sigma-Aldrich, St. Louis, MO, USA) and 5 mL/500 ml of ITS (Becton Dickinson cat. no. 354352, NJ, USA) in the absence (untreated) or presence of cisplatin 0.5 and 1 μg/ml for 48 hours plus 24 of recovery plus 100 μM EPA.
Immunofluorescence Analysis
The untreated SCs and SCs treated with chemotherapeutic drugs (plus EPA or without EPA), were made to grow on round slides pre-treated with gelatine (Sigma-Aldrich). At the end of the treatment, the SCs were fixed for 30 min in 4% paraformaldehyde in phosphate buffer (PBS). Prior to immunolabelling, the cells were subjected to permeabilization (PBS, 0.2% Triton X) for 5 min at room temperature, blocked in 0.5% bovine serum albumin (BSA; Sigma-Aldrich, St. Louis, MO) in PBS for 10 min, and then exposed to the primary anti-5hmC antibody (Santa Cruz Biotechnology, 1:100 in PBS) overnight at 4° C. The cells were washed three times in PBS for 5 min and then exposed to the secondary Alexa-488 labelled antibody (1:500 in PBS). The cells were counterstained with 4′,6-diamidino-2-phenylindole (DAPI) for 1 min after treatment with RNase (10 mg/mL per 10 min.). The negative control for the immunolabelling consisted in skipping the labelling with the primary antibody and passing directly to the secondary antibody. The slides were then mounted with ProLong® Gold Antifade (ThermoFisher) and the images were acquired with an Olympus BX-41 equipped with Cell-F image processing software (Olympus).
Real-Time PCR Analysis
Total RNA was isolated from the monolayers of untreated SCs and SCs treated with chemotherapeutic drugs (plus EPA or without EPA) by means of an RNA purification kit (Versagene RNA Cell Kit, Gentra Systems, Minneapolis, MN) and quantified by reading the optical density at 260 nm. Subsequently, 1 μg of total RNA was subjected to RT in a final volume of 20 μl by means of the Maxima First Strand cDNA Synthesis kit (Thermo Scientific, MA, USA). Real-time PCR was performed using 16 ng of cDNA, prepared from the RT reaction, and SYBR Green (Stratagene, Amsterdam, Netherlands). Real-time PCR was performed with an Mx3000P cycler (Stratagene) using FAM for detection and ROX as the reference dye. The level of mRNA for each sample was normalised with respect to the mRNA of β-actin and expressed as a change compared to the level of the untreated control cells.
Western Blotting Analysis
The SCs were cultured at 37° C. and 5% CO2 in HAMF-12 (Euroclone, MI, Italy) supplemented with 0.166 nM of retinoic acid (Sigma-Aldrich, St. Louis, MO, USA) and 5 mL/500 ml of ITS (Becton Dickinson cat. no. 354352, NJ, USA) in the absence (untreated) or presence of cisplatin 0.5 and 1 μg/ml for 48 hours plus 24 of recovery and with the addition of 100 μM EPA. 70 μg of proteins obtained from the total cell lysate were subjected to SDS gel electrophoresis, then electroblotted on a nitrocellulose membrane (SchleicherandSchuell, Keene, NH, USA) and labelled with an anti-5hmC antibody (Santa Cruz Biotechnology). The immunoreactive bands were visualised by means of an ECL assay (Amersham Pharmacia Biotech, Little Chalfont, UK). The anti-β-tubulin antibody (Sigma-Aldrich) was used as a normaliser. The images were acquired by means of the VersaDoc Imaging System (Bio-Rad Hercules, CA, USA), and the respective signals were quantified using Quantity One software (Bio-Rad) 2.8.
Analysis of the Secretion of Inhibin B and AMH
At the end of the treatment with the chemotherapeutic drugs, aliquots of the supernatants were collected from cultures of untreated SCs and SCs treated with the chemotherapeutic drugs (plus EPA or without EPA) and stored at −20° C. for the assessment of inhibin B and AMH secretion by ELISA (Inhibin B Gen II ELISA kit, Beckman Coulter, Webster, TX, U.S.A., within the tests CV=2.81%; between the tests CV=4.33%), (AMH Gen II ELISA kit, Beckman Coulter, Webster, TX, U.S.A., within the tests CV=3.89%; between the tests CV=5.77%), as previously described (Luca et al., 2015).
Statistical Analysis
The results shown in the figures were the mean±S.E.M of three independent experiments, each carried out in triplicate. The statistical analysis was performed by means of a paired Student T-test.
Results
The data obtained demonstrated (
This effect is likely to be correlated to the epigenetic action of EPA, whose demethylating action has been demonstrated (Ceccarelli V et al., 2018). In fact, by treating the cells with AZA (5-aza-2′-deoxycytidine), a known demethylating agent used in the chemotherapeutic treatment of tumour pathologies, one obtains a recovery comparable to that induced by treatment with the fatty acid.
| Number | Date | Country | Kind |
|---|---|---|---|
| 102020000026798 | Nov 2020 | IT | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/IT2021/050364 | 11/9/2021 | WO |
